Therapie der clozapin-induzierten hypersalivation mit botulinum-toxin B

K. G. Kahl; P. Trillenberg; A. Kordon; R. Lencer; C. Klein; J. Hagenah

doi:10.1007/s00115-004-1800-x

Therapie der clozapin-induzierten hypersalivation mit botulinum-toxin B

K. G. Kahl^*, P. Trillenberg, A. Kordon, R. Lencer, C. Klein, J. Hagenah

^*Korrespondierende/r Autor/-in für diese Arbeit

6 Zitate (Scopus)

Abstract

Hypersalivation is frequently observed in patients treated with clozapine. Current strategies to counteract sialorrhea include the introduction of antimuscarinergic (anticholinergic) and α ₂-agonistic treatment. However, the use of these substances is limited in part by lack of efficacy and by adverse side effects. In cases of intractable sialorrhea, the application of botulinum toxin may be a new and safe therapeutic option. We here present an overview on current treatment strategies for sialorrhea and describe a patient who received botulinum toxin B for clozapine-induced hypersalivation.

Titel in Übersetzung	Pharmacological strategies for clozapine-induced hypersalivation: Treatment with botulinum toxin B in one patient and review of the literature
Originalsprache	Deutsch
Zeitschrift	Nervenarzt
Jahrgang	76
Ausgabenummer	2
Seiten (von - bis)	205-208
Seitenumfang	4
ISSN	0028-2804
DOIs	https://doi.org/10.1007/s00115-004-1800-x
Publikationsstatus	Veröffentlicht - 01.02.2005

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

Dokumente

10.1007/s00115-004-1800-x

Weitere Links

Link to publication in Scopus

Zitieren

@article{806ca06893bd49deb51404fe05c117d2,

title = "Therapie der clozapin-induzierten hypersalivation mit botulinum-toxin B",

abstract = "Hypersalivation is frequently observed in patients treated with clozapine. Current strategies to counteract sialorrhea include the introduction of antimuscarinergic (anticholinergic) and α 2-agonistic treatment. However, the use of these substances is limited in part by lack of efficacy and by adverse side effects. In cases of intractable sialorrhea, the application of botulinum toxin may be a new and safe therapeutic option. We here present an overview on current treatment strategies for sialorrhea and describe a patient who received botulinum toxin B for clozapine-induced hypersalivation.",

author = "Kahl, {K. G.} and P. Trillenberg and A. Kordon and R. Lencer and C. Klein and J. Hagenah",

year = "2005",

month = feb,

day = "1",

doi = "10.1007/s00115-004-1800-x",

language = "Deutsch",

volume = "76",

pages = "205--208",

journal = "Nervenarzt",

issn = "0028-2804",

number = "2",

}

TY - JOUR

T1 - Therapie der clozapin-induzierten hypersalivation mit botulinum-toxin B

AU - Kahl, K. G.

AU - Trillenberg, P.

AU - Kordon, A.

AU - Lencer, R.

AU - Klein, C.

AU - Hagenah, J.

PY - 2005/2/1

Y1 - 2005/2/1

N2 - Hypersalivation is frequently observed in patients treated with clozapine. Current strategies to counteract sialorrhea include the introduction of antimuscarinergic (anticholinergic) and α 2-agonistic treatment. However, the use of these substances is limited in part by lack of efficacy and by adverse side effects. In cases of intractable sialorrhea, the application of botulinum toxin may be a new and safe therapeutic option. We here present an overview on current treatment strategies for sialorrhea and describe a patient who received botulinum toxin B for clozapine-induced hypersalivation.

AB - Hypersalivation is frequently observed in patients treated with clozapine. Current strategies to counteract sialorrhea include the introduction of antimuscarinergic (anticholinergic) and α 2-agonistic treatment. However, the use of these substances is limited in part by lack of efficacy and by adverse side effects. In cases of intractable sialorrhea, the application of botulinum toxin may be a new and safe therapeutic option. We here present an overview on current treatment strategies for sialorrhea and describe a patient who received botulinum toxin B for clozapine-induced hypersalivation.

UR - http://www.scopus.com/inward/record.url?scp=14544308876&partnerID=8YFLogxK

U2 - 10.1007/s00115-004-1800-x

DO - 10.1007/s00115-004-1800-x

M3 - Zeitschriftenaufsätze

C2 - 15448913

AN - SCOPUS:14544308876

SN - 0028-2804

VL - 76

SP - 205

EP - 208

JO - Nervenarzt

JF - Nervenarzt

IS - 2

ER -

Therapie der clozapin-induzierten hypersalivation mit botulinum-toxin B

Abstract

UN SDGs

Dokumente

Weitere Links

Fingerprint

Zitieren